Trial
NCT01721317
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
Bausch Health Americas, Inc.
Condition
Seizures
Intervention
Ezogabine/Retigabine IR
Why stopped
After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-30